BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

KT-seminar-The_Promise_of_Regenerqtion_Medicine_and_AI-Fb_bannernew

CERN seminar: The Promise of Regenerative Medicine and AI

During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.

Swiss-based Altium major investor BioStock

BioStock: PHI catches eye of major investor

BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.

Patrik Eschricht and Peter Egelberg shaking hands

February 15, 2023

BioStock: PHI comments on the new senior positions in the company

BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.

PHI CSO Kersti Alm at Biostock

November 23, 2022

BioStock: PHI on the alliance for cell-based biomanufacturing

Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.

1…6 789 10